Formycon Dividends and Buybacks
Dividend criteria checks 0/6
Formycon does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.05%
Buyback Yield
| Total Shareholder Yield | -0.05% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
FYB: Confirmed 2025 And 2026 Revenue Guidance Will Support Bullish Outlook
Analysts have trimmed their price target for Formycon slightly to about €39.67 from around €39.86. This reflects updated views on discount rates, growth assumptions and future P/E expectations.FYB: Reaffirmed 2025 And 2026 Revenue Guidance Will Support Bullish Outlook
Analysts have marginally adjusted their price target for Formycon, with fair value moving from about €40.14 to €39.86, citing updated assumptions for revenue growth, profit margins, and future P/E levels. What's in the News Formycon confirmed earnings guidance for 2026, with the group expecting revenue in a range of €60.0 million to €70.0 million.FYB: Future Earnings Guidance And Biosimilar Progress Will Support Bullish Outlook
Analysts have raised their price target for Formycon from €35.69 to €40.14, citing updated assumptions around revenue growth, profit margins, and the P/E multiple used in their models. What's in the News Formycon issued earnings guidance for 2026, with the group expecting revenue in a range of €60.0 million to €70.0 million.
Regulatory Tailwinds And Biosimilar Royalties Will Slowly Overcome Concentrated Pipeline Risks
Catalysts About Formycon Formycon develops and commercializes biosimilar medicines in collaboration with partners across global markets. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Biosimilar Pipeline Will Reshape Long Term Earnings Power
Catalysts About Formycon Formycon develops and commercializes biosimilar medicines, focusing on high-value biologics in ophthalmology, immunology and oncology. What are the underlying business or industry changes driving this perspective?
Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline
The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon.A Look At The Fair Value Of Formycon AG (ETR:FYB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Formycon fair value estimate is €60.63 Current share price of...Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares
Formycon AG's ( ETR:FYB ) price-to-earnings (or "P/E") ratio of 10.3x might make it look like a buy right now compared...We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability
Formycon AG ( ETR:FYB ) recently released a strong earnings report, and the market responded by raising the share...Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S
With a price-to-sales (or "P/S") ratio of 11.4x Formycon AG ( ETR:FYB ) may be sending bearish signals at the moment...We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up
You may think that with a price-to-sales (or "P/S") ratio of 12.8x Formycon AG ( ETR:FYB ) is a stock to avoid...We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings
The recent earnings posted by Formycon AG ( ETR:FYB ) were solid, but the stock didn't move as much as we expected. We...We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)
Shareholders in Formycon AG ( ETR:FYB ) may be thrilled to learn that the analysts have just delivered a major upgrade...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.
Dividend Yield vs Market
| Formycon Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (FYB) | n/a |
| Market Bottom 25% (DE) | 1.4% |
| Market Top 25% (DE) | 4.8% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (FYB) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FYB's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FYB has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 23:58 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Formycon AG is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Benjamin Thielmann | Berenberg |
| Christian Ehmann | Berenberg |